The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission

Leuk Lymphoma. 2019 Dec;60(13):3099-3101. doi: 10.1080/10428194.2019.1665667. Epub 2019 Sep 26.

Authors

Claire Andrews¹, Jeffrey Lipton¹

Affiliation

¹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

PMID: 31556337
DOI: 10.1080/10428194.2019.1665667

No abstract available

MeSH terms

Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / epidemiology*
Cardiovascular Diseases / prevention & control
Dose-Response Relationship, Drug
Fusion Proteins, bcr-abl / antagonists & inhibitors
Fusion Proteins, bcr-abl / genetics
Humans
Imidazoles / administration & dosage*
Imidazoles / adverse effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Mutation
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / adverse effects
Pyridazines / administration & dosage*
Pyridazines / adverse effects
Risk Factors
Treatment Outcome

Substances

BCR-ABL1 fusion protein, human
Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib
Fusion Proteins, bcr-abl